$59.24 Million in Sales Expected for Tabula Rasa HealthCare Inc (TRHC) This Quarter

Analysts expect that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will report $59.24 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Tabula Rasa HealthCare’s earnings, with the highest sales estimate coming in at $61.50 million and the lowest estimate coming in at $57.50 million. Tabula Rasa HealthCare posted sales of $43.94 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 34.8%. The company is scheduled to report its next earnings report on Tuesday, May 14th.

On average, analysts expect that Tabula Rasa HealthCare will report full-year sales of $284.89 million for the current financial year, with estimates ranging from $283.10 million to $286.40 million. For the next fiscal year, analysts forecast that the firm will report sales of $350.21 million, with estimates ranging from $332.80 million to $362.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its earnings results on Thursday, February 28th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.07). The firm had revenue of $57.31 million during the quarter, compared to analysts’ expectations of $55.70 million. Tabula Rasa HealthCare had a negative net margin of 23.14% and a positive return on equity of 7.76%.

A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Thursday, December 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $80.00 price target on shares of Tabula Rasa HealthCare in a report on Thursday, December 6th. BidaskClub lowered Tabula Rasa HealthCare from a “sell” rating to a “strong sell” rating in a report on Saturday, February 9th. Oppenheimer lowered their target price on Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, March 6th. Finally, First Analysis raised Tabula Rasa HealthCare from an “outperform” rating to a “strong-buy” rating and set a $58.33 target price on the stock in a report on Monday, March 11th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $83.48.

In related news, insider Andrea Carolan Speers sold 1,022 shares of the company’s stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $58.08, for a total value of $59,357.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Brian W. Adams sold 3,035 shares of the company’s stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $57.45, for a total value of $174,360.75. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock worth $3,175,138 in the last ninety days. 14.00% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in shares of Tabula Rasa HealthCare by 1.6% in the 4th quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock valued at $165,831,000 after purchasing an additional 40,174 shares during the last quarter. M&T Bank Corp purchased a new position in Tabula Rasa HealthCare in the fourth quarter valued at approximately $33,749,000. Peregrine Capital Management LLC lifted its stake in Tabula Rasa HealthCare by 8.1% in the fourth quarter. Peregrine Capital Management LLC now owns 263,096 shares of the company’s stock valued at $16,775,000 after purchasing an additional 19,705 shares during the last quarter. Fiera Capital Corp purchased a new position in Tabula Rasa HealthCare in the fourth quarter valued at approximately $2,268,000. Finally, Morgens Waterfall Vintiadis & Co. Inc. lifted its stake in Tabula Rasa HealthCare by 33.3% in the third quarter. Morgens Waterfall Vintiadis & Co. Inc. now owns 16,000 shares of the company’s stock valued at $1,299,000 after purchasing an additional 4,000 shares during the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.

NASDAQ:TRHC traded down $2.46 on Wednesday, reaching $53.96. The stock had a trading volume of 326,685 shares, compared to its average volume of 412,814. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 158.71 and a beta of 1.65. The company has a current ratio of 0.84, a quick ratio of 0.79 and a debt-to-equity ratio of 0.32. Tabula Rasa HealthCare has a 12-month low of $35.50 and a 12-month high of $91.16.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

See Also: What does RSI mean?

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.